News and Events

Next Generation Risk Assessment (NGRA) is pushing toxicology toward scalable, animal-free approaches that connect molecular perturbations to real biological outcomes.​ At SOT 2026, Alithea Genomics will present DRUG-seq, a high-throughput transcriptomics platform that enables cost-efficient gene expression profiling at scale. We will also show how integrating transcriptomics with phenotypic assays, like Cell Painting, can strengthen the mechanistic understanding of chemical effects.​ Join our exhibitor-hosted session titled “Transcriptomics at Scale: Powering Multiomics Strategies for NGRA” featuring invited speakers, Fred Ward and Richard Currie, sharing real-world multi-omics applications, demonstrating how transcriptomics, imaging, and other omics technologies can be combined to support NGRA-driven decision making in toxicology.​ If you are attending SOT, join us to explore how multi-omics approaches are accelerating mechanism-based safety assessment.​

🎤 Don’t miss our joint session with Bayer! (Mon, Jan 12 | 4:00–6:10 PM | Pacific C) Unlock the Power of High-throughput Transcriptomics with BRB-seq Tailored to Plant and Animal Research Computational Multiplexed Transcriptomic Analysis: Modes of Action in the Fungal Plant Pathogen Botrytis cinerea